William Walsh

Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Steven J. Kuerbitz, Beverly Plunkett, William Walsh et al. · Proceedings of the National Academy of Sciences · 1992 · 1.9K citations

Medicine, Cell Biology, Oncology +15

Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis

Sameer A. Parikh, Hagop M. Kantarjian, Aaron D. Schimmer et al. · Clinical Lymphoma Myeloma & Leukemia · 2010 · 87 citations

Medicine, Hematology, Pharmacology +14

Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience

Mohammed Salhab, Yazan Migdady, Melanie Donahue et al. · Journal for ImmunoTherapy of Cancer · 2018 · 31 citations · Full text

Medicine, Oncology, Pathology +17

Population‐based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease

John M. Varlotto, Richard Voland, Kerrie McKie et al. · Cancer Medicine · 2018 · 27 citations · Full text

Medicine, Oncology, Cancer Epidemiology +15

Docetaxel, Estramustine, and 15-Month Androgen Deprivation for Men With Prostate-Specific Antigen Progression After Definitive Local Therapy for Prostate Cancer

Mary-Ellen Taplin, Wanling Xie, Glenn J. Bubley et al. · Journal of Clinical Oncology · 2006 · 25 citations · Full text

Medicine, Oncology, Urology +17